期刊文献+

细胞能量矛盾——帕金森病进展的主要推动力及防治对策 被引量:2

Energy Pressure of the Cell is the Primal Driving Force in the Progression of Parkinson Disease and the Prevention Strategy of It
下载PDF
导出
摘要 帕金森病是常见的老年神经变性疾病,目前机制不清,无有效的治疗方法。线粒体功能障碍与帕金森病密切相关。认为,某些常见的环境因素和身体状态,如环境毒物、受寒、人体的免疫反应、炎症因子、感染、应激状态等,可导致多巴胺能神经元等常见易损伤的细胞发生能量矛盾,并因此造成线粒体损伤累积,认为这是导致帕金森病发病和病情进展的主要推动力。针对能量矛盾的产生,采取减少能量干扰和促进线粒体功能的策略,将会对阻止帕金森病的进展和研发有效的治疗方法,起到良好的促进作用。 Parkinson Disease is a common neurodegenerative movement disorder in elderly people without complete understanding of it's mechanism and with no effective therapies .This disease is closely related with the dysfunction of mitochondria .Some common environmental factors and physical status of the patients ,such as toxic substances of some drugs and pesticides ,cold weather ,immune response ,inflammation and inflammatory factors ,stress ,could induce energy pressure in the fragile dopaminergic cells and cause injuries accumulated in mitochondria ,which could be the driving force of this disease .The strategies to prevent the occurrence of energy pressure and to improve the energy producing ability of mitochondria might be important in preventing the progress of this disease .
作者 唐勇 白群华
出处 《医学与哲学(B)》 2015年第6期68-70,共3页 Medicine & Philosophy(B)
基金 重庆市科委前沿与应用基础研究计划项目基金 项目编号:cstc2014jcyjA10019
关键词 帕金森病 能量矛盾 疾病进展 防治对策 Parkinson Disease, energy pressure, disease progression mechanism, prevention strategy
  • 相关文献

参考文献19

  • 1梁杨,顾英,孙亚南,李晓红.帕金森病早期诊断之生物学标记物[J].医学与哲学(B),2014,35(9):66-69. 被引量:2
  • 2Gao H M,Hong J S. Gene-environment interactions:key to unrave- ling the mystery of Parkinson's disease[J].Prog Neurobiol, 2011,94 (1) :1--19.
  • 3Rebecca B,Anatoly A S,Beal M F, et al. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis[J]. Biochim Biophys Acta, 2009,1792(7) : 651 -- 663.
  • 4Dodson M W,Guo M. Pinkl,Parkin,DJ 1 and mitochondrial dys- function in Parkinson's disease[J]. Curr Opin Neurobiol, 2007,17 (3) :331--337.
  • 5Bovfi J, Prou D, Perier C, et al. Toxin-Induced Models of Parkinsoffs Disease[J].NeuroRx,2005,2(3) :484--494.
  • 6Bolam J P,Pissadaki E K. Living on the edge with too many mouths to feed: why dopamine neurons die[J]. Mov Disord, 2012,27 ( 12 ) : 1478--1483.
  • 7帕夫.脑觉醒与信息理论:神经和遗传机制[M].郑瑞茂,译.北京:北京大学医学出版社,2008:86.
  • 8Asahina M, Vichayanrat E, Low D A, et al. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology[J].] Neurol Neurosurg Psychiatry,2013,84 (6) : 674-- 680.
  • 9van der Vegt J P,van Nuenen B F,Bloem B R,et al. Imaging the impact of genes on Parkinson's disease[J].Neuroscience, 2009,164 (1):191 204.
  • 10Kweon G R, Marks J D, Krencik R, et al. Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in do- paminergic and non-dopaminergic cells[J].J Biol Chem, 2004,279 (50) :51783--51792.

二级参考文献33

  • 1逯改.传媒社会责任的伦理审视[J].兰州学刊,2007(9):149-152. 被引量:11
  • 2张艳萍,陈惠,王夏玲.医患关系“尖峰时刻”[N].医师报,2011一09—22(3).
  • 3佚名.医疗纠纷困扰医院[EB/OL].(2002-03-11)[2011-12-20].http://www.51qe.cn/pic/45/26/1l/18/027.htm.
  • 4基兰.媒体伦理[M].南京:南京大学出版社,2009:3334.
  • 5Pahwa R, Lyons K E. Early diagnosis of Parkinson's disease.-recom- mendations from diagnostic clinical guidelines [J]. Am J Manag Care, 2010,16(4) : 94- 99.
  • 6Le Witt P, Schultz L, Auinger P. GSF xanthine, homovanillie acid, and their ratio as biomakers of Parkinson's disease[J]. Brain Res, 2011,1408:88-97.
  • 7Shi M,Bradner J, Hancock A M, et al. Cerebrospinal fluid biomak- ers for Parkinson's disease diagnosis and progression[J]. Ann Neu- rol,2011,69:570-580.
  • 8Yanamandra K, Gruden M A, Casaite V, et al. synuclein reactive an- tibodies as diagnostic biomarkers in blood sera of Parkinson's dis- ease patients [J]. PLoS One,2011,6(4) :E18513.
  • 9E1-Agnaf O M,Salem S A,Paleologou K E,et al. Detection of oligo- meric forms of alpha-synuclein protein in human plasma as a poten- tial biomarker for Parkinson's disease[J]. FASEB J, 2006,20 ( 3 ) : 419-425.
  • 10Foulds P G, Mitchell J D,Parker A, et al. Phosphorylated alpha synucle- in can be detected in blood plasma and is potentiaily a useful biomarker for Parkinson's disease[J]. FASEB J,2011,25(12) :4127-4137.

共引文献7

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部